Recent case reports of acute pancreatitis in patients with type 2 diabetes (T2DM) treated
with incretin‐based therapies have triggered interest regarding the possibility of a …

Abstract Sitagliptin (Januvia®, Xelevia™, Glactiv®, Tesavel®) is an orally administered,
potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first …

Background In a previous pooled analysis of 12 double-blind clinical studies that included
data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase …

Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) play an increasing role in
the management of type 2 diabetes. Such incretin-based therapies offer some advantages …

Introduction In a previous pooled analysis of 19 double-blind clinical studies conducted by
Merck, which included data available as of July 2009 on 10,246 patients with type 2 …

Background Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new
class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 …

The dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia®; Glactiv®; Tesavel®; Xelevia™) is
approved in more than 130 countries worldwide as monotherapy and in combination with …

In 2007 a question was raised about the causal relationship between the first of the
glucagon-like peptide 1 receptor agonists, exenatide, and pancreatitis, as postmarketing …

Objective To determine if the use of sitagliptin in newly treated patients with type 2 diabetes
is associated with any changes in clinical outcomes. Design Retrospective population based …

Introduction: The ever-increasing burden of type 2 diabetes mellitus (T2DM) and inadequate
control in the majority of patients has led to a quest for newer therapeutic options. There …